Investigational drug · Phase 3
PF-07248144
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
11
Any phase or sponsor naming "PF-07248144"
First trial start
2020
Nov 16, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-07248144", any sponsor or status.
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic ER+ HER2- Breast Cancer
- Locally Advanced or Metastatic Castration-resistant Prostate Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-07248144" as an intervention, largest first.
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07062965 · 400 participants (planned) · Start Aug 5, 2025 · Primary completion Jul 22, 2027
Drug: PF-07248144; Fulvestrant and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Gilbert, Arizona · 433 sites in all
PfizerPfizer (PFE)
NCT04606446 · 320 participants (planned) · Start Nov 16, 2020 · Primary completion Aug 27, 2029
Drug: PF-07248144; Fulvestrant and 4 more · For: Locally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer; Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sites: Scottsdale, Arizona; Los Angeles, California; San Francisco, California · 43 sites in all
UNICANCERAcademic, hospital or other
NCT07340619 · 51 participants (planned) · Start Sep 18, 2026 · Primary completion Nov 18, 2028
Drug: prifetrastat monotherapy for 15 days then combination with fulvestrant; prifetrastat in combination with fulvestrant · For: Metastatic (Stage IV) Melanoma
Sites: Bordeaux, France; Lyon, France; Marseille, France · 8 sites in all
- A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal ImpairmentNot yet recruiting
PfizerPfizer (PFE)
NCT07933848 · 24 participants (planned) · Start Nov 17, 2026 · Primary completion May 21, 2028
Drug: Prifetrastat · For: Renal Impairment; Healthy Adults
Sites: Miami Lakes, Florida; Tampa, Florida; Saint Paul, Minnesota
PfizerPfizer (PFE)
NCT07117799 · 24 participants · Start Feb 4, 2025 · Primary completion Jun 18, 2025
Drug: PF-07248144; PF-07248144 and 1 more · For: Healthy Adults
Sites: New Haven, Connecticut
- A Study to Learn if Itraconazole Changes How the Body Processes PF-07248144 (Study Medicine)Completed
PfizerPfizer (PFE)
NCT07335419 · 12 participants · Start Jan 2, 2026 · Primary completion Feb 22, 2026
Drug: PF-07248144; Itraconazole · For: Healthy Adult Participants
Sites: New Haven, Connecticut
- A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy AdultsNot yet recruiting
PfizerPfizer (PFE)
NCT07731100 · 12 participants (planned) · Start Jul 24, 2026 · Primary completion Sep 10, 2026
Drug: Prifetrastat · For: Healthy Adults
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT07636018 · 12 participants · Start Aug 26, 2025 · Primary completion Oct 8, 2025
Drug: PF-07248144; Fluconazole · For: Healthy Adults
Sites: Brussels, Belgium
PfizerPfizer (PFE)
NCT07198035 · 12 participants · Start Sep 18, 2025 · Primary completion Dec 17, 2025
Drug: PF-07248144; Carbamazepine · For: Healthy Adults
Sites: Brussels, Belgium
PfizerPfizer (PFE)
NCT07578636 · 9 participants · Start May 18, 2026 · Primary completion Jul 2, 2026
Drug: Oral [14C] PF-07799544; Oral Unlabeled PF-07799544 and 1 more · For: Healthy Male Volunteers
Sites: Madison, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents.
Woodland R, Suwandi A, Teklemariam AB, et al. · ChemMedChem 2026
- KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress.
Mukohara T · Expert Opin Investig Drugs 2026
- Dancing with KAT6A: Current advances and therapeutic potential in oncology of KAT6A inhibitors.
Xi Z, Wang J, Ge X, et al. · Bioorg Chem 2026
- Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Mukohara T, Park YH, Sommerhalder D, et al. · Nat Med 2024
Also in development for Locally Advanced or Metastatic ER+ HER2- Breast Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.